Clinical Trial Update: Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating daratumumab as first-line therapy in transplant-ineligible multiple myeloma patients, with possible daratumumab retreatment at fir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: University of Cologne | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING